Journal of the Society for Cardiovascular Angiography & Interventions最新文献

{"title":"Incidence of Complications Following Coronary Intravascular Lithotripsy, Clinical Outcomes, and Predictors of Complications","authors":"Martijn J.H. van Oort MSc ,&nbsp;Akshay A.S. Phagu MD ,&nbsp;Federico Oliveri MD ,&nbsp;Brian O. Bingen MD, PhD ,&nbsp;Valeria Paradies MD ,&nbsp;Gianluca Mincione MD ,&nbsp;Bimmer E.P.M. Claessen MD, PhD ,&nbsp;Aukelien C. Dimitriu-Leen MD, PhD ,&nbsp;Tessel N. Vossenberg MD ,&nbsp;Joelle Kefer MD, PhD ,&nbsp;Hany Girgis MD ,&nbsp;Frank van der Kley MD, PhD ,&nbsp;J. Wouter Jukema MD, PhD ,&nbsp;Ibtihal Al Amri MD, PhD ,&nbsp;Jose M. Montero-Cabezas MD, PhD","doi":"10.1016/j.jscai.2025.103706","DOIUrl":"10.1016/j.jscai.2025.103706","url":null,"abstract":"<div><h3>Background</h3><div>This study aimed to evaluate the incidence of complications associated with intravascular lithotripsy (IVL) therapy, assess clinical outcomes, and identify predictors of complications in a real-world patient cohort.</div></div><div><h3>Methods</h3><div>Patients undergoing IVL between May 2019 and September 2024 were enrolled from the BENELUX-IVL registry and categorized based on the occurrence of complications following IVL and concomitant therapy. End points were achievement of residual diameter stenosis &lt;30% on quantitative coronary analysis and major adverse cardiovascular events (MACE) at 1-year follow-up. Kaplan-Meier and binary logistic regression analyses were performed to compare outcomes and to identify predictors of complications.</div></div><div><h3>Results</h3><div>The study included 509 patients (73 ± 9 years, 75% male). Complications occurred in 33 patients (6%), of which 6 complications occurred immediately after IVL (1%). The most frequent complications were flow-limiting coronary dissections (n = 9, 2%), hemodynamic instability (n = 9, 2%), and coronary perforations (n = 7, 1%). These were effectively managed with 30 interventions, resulting in favorable procedural outcomes. Among patients with complications and available quantitative coronary analysis data, residual diameter stenosis &lt;30% was achieved in 28 of 29 lesions (97%). One-year cumulative MACE was 11% (39 patients) and was significantly higher in patients with complications (<em>P</em> &lt; .001), mainly driven by in-hospital events (<em>P</em> &lt; .001). Larger predilatation balloon diameters (<em>P</em> = .032) were associated with complications.</div></div><div><h3>Conclusions</h3><div>In this real-world registry, complications following IVL and concomitant therapy were infrequent. Patients with procedural complications had significantly higher 1-year MACE, primarily driven by in-hospital events. Larger predilatation balloon diameters were a significant predictor of complications.</div></div>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 8","pages":"Article 103706"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144863225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in Mortality Among Adults With Acute Myocardial Infarction With Cardiogenic Shock in the United States, 1999-2023","authors":"Abdullah Naveed Muhammad MBBS ,&nbsp;Sivaram Neppala MD ,&nbsp;Himaja Dutt Chigurupati MD ,&nbsp;Bazil Azeem MBBS ,&nbsp;Rabia Iqbal MBBS ,&nbsp;Muhammad Omer Rehan MBBS ,&nbsp;Priya Hotwani MD ,&nbsp;Ahila Ali MBBS ,&nbsp;Sowjanya Kapaganti MD ,&nbsp;Mushood Ahmed MBBS ,&nbsp;Mobeen Zaka Haider MD ,&nbsp;Yasar Sattar MD, MS ,&nbsp;Jamal S. Rana MD ,&nbsp;Sourbha Dani MD","doi":"10.1016/j.jscai.2025.103711","DOIUrl":"10.1016/j.jscai.2025.103711","url":null,"abstract":"<div><h3>Background</h3><div>Cardiogenic shock (CS) elevates mortality rates among patients with acute myocardial infarction (AMI), yet there are insufficient data on trends in mortality. This study seeks to elucidate demographic patterns and mortality statistics.</div></div><div><h3>Methods</h3><div>We analyzed data from the Centers for Disease Control and Prevention's Wide-ranging ONline Data for Epidemiologic Research (1999-2023) to evaluate mortality related to CS among AMI patients aged 25 years and above. Age-adjusted mortality rates (AAMR) per 100,000 patients and average annual percentage changes were calculated using JoinPoint regression analysis to explore mortality trends.</div></div><div><h3>Results</h3><div>Cardiogenic shock contributed to 187,838 deaths among AMI patients aged 25 years and older. Between 1999 and 2023, the AAMR fell from 5.4 to 3.3 per 100,000, reflecting an average annual percentage change of –2.02. The most significant reduction occurred from 1999 to 2011, followed by a notable increase from 2011 to 2021 (annual percent change, 3.32). Disparities are apparent, as men have higher AAMR than women (4.5 vs 2.5), with Hispanic individuals at the most significant risk (AAMR, 3.5), followed by Whites (AAMR, 3.4). Regionally, West Virginia has the highest AAMR at 5.3, whereas Minnesota has the lowest at 2.3. Additionally, rural areas report higher AAMR than urban ones (4.0 vs 3.2).</div></div><div><h3>Conclusions</h3><div>The recent increase in mortality rates between 2011 and 2021 due to CS in AMI and disparities among men, Hispanic individuals, and people living in rural areas—calls for urgent attention. By applying focused interventions and improving health care access, we can bridge these gaps and enhance patient outcomes.</div></div>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 7","pages":"Article 103711"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144680139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcatheter Aortic Valve Replacement for Aortic Regurgitation in Patients with Left Ventricular Assist Devices: An Institutional Experience","authors":"Hanad Bashir MD,&nbsp;Gustavo Mendez-Hirata MD,&nbsp;Christian W. Schmidt MS,&nbsp;Alan Wong MD,&nbsp;Janelle Muuse MD,&nbsp;Gregory F. Egnaczyk MD,&nbsp;Dean J. Kereiakes MD,&nbsp;Puvi Seshiah MD,&nbsp;Raviteja R. Guddeti MD,&nbsp;Nadia El-Hangouche MD,&nbsp;Santiago Garcia MD","doi":"10.1016/j.jscai.2025.103662","DOIUrl":"10.1016/j.jscai.2025.103662","url":null,"abstract":"<div><h3>Background</h3><div>Aortic regurgitation (AR) is a common complication in patients with left ventricular assist devices (LVAD). However, there is paucity of data regarding the feasibility and safety of transcatheter aortic valve replacement (TAVR) in this population. Hence, we sought to describe the clinical characteristics and outcomes of patients with LVAD and AR who underwent treatment with TAVR at our institution.</div></div><div><h3>Methods</h3><div>We included all patients with a LVAD who developed clinically significant AR and received TAVR at The Christ Hospital in Cincinnati, Ohio. Baseline clinical and echocardiographic characteristics were collected, and outcomes were defined using Valve Academic Research Consortium 3 criteria.</div></div><div><h3>Results</h3><div>A total of 7 patients with LVAD were included. The median time from LVAD implantation to TAVR was 3.67 years (IQR, 1.96-4.26 years). The mean age of the patients was 68.6 ± 13.7 years, and the average Society of Thoracic Surgeons score was 6.2 ± 5.2. All patients presented with moderate to severe AR and New York Heart Association functional class III or IV symptoms. All procedures were performed via transfemoral access, with a median procedure time of 149 minutes (IQR, 146-150 minutes). The transcatheter heart valves implanted included commercially available devices—Abbott Navitor (n = 2) and Medtronic Evolut (n = 3)—and dedicated investigational devices for AR—JenaValve Trilogy (n = 1) and J-Valve (n = 1). All patients were discharged alive with no or mild residual AR. There was 1 case of device embolization, which was treated with a second valve, and 1 valve migration treated with snaring and repositioning of the valve. Both complications occurred in patients treated with commercially available self-expanding valves.</div></div><div><h3>Conclusions</h3><div>TAVR for AR in selected patients with LVAD is a feasible therapeutic option that may improve outcomes. Larger studies are necessary to better define procedural risks, optimal patient selection, and the role of TAVR valves specifically designed for AR in this population.</div></div>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 7","pages":"Article 103662"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144680144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and Predictors of High-Grade AV Block in Patients With Initially Unchanged Electrocardiogram After TAVR","authors":"Mohamed Elhadi MB BCh, BAO,&nbsp;Mohamad S. Alabdaljabar MBBS,&nbsp;Conor Lane MB BCh, BAO,&nbsp;Abhishek J. Deshmukh MBBS,&nbsp;Rajiv Gulati MD, PhD,&nbsp;Yong-Mei Cha MD,&nbsp;Mackram F. Eleid MD","doi":"10.1016/j.jscai.2025.103666","DOIUrl":"10.1016/j.jscai.2025.103666","url":null,"abstract":"<div><h3>Background</h3><div>High-grade atrioventricular block (HAVB) is common after transcatheter aortic valve replacement (TAVR). We compared patients with baseline conduction disease that is unchanged on the immediate post-TAVR echocardiogram (ECG) to patients with normal baseline and post-TAVR ECG (control group).</div></div><div><h3>Methods</h3><div>Consecutive patients who underwent TAVR at Mayo Clinic (Rochester, Minnesota) between February 2012 and December 2021 were retrospectively reviewed.</div></div><div><h3>Results</h3><div>In total, 1069 patients were included in the study: 825 controls, 44 with isolated PR of &gt;240 milliseconds, 93 with left bundle branch block (LBBB), and 107 with right bundle branch block (RBBB). Early HAVB (&lt;24 hours post-TAVR) occurred more frequently in the RBBB group compared with controls (11.2% vs 0.6%; <em>P</em> &lt; .001). Early HAVB incidence was similar between the control, isolated PR &gt;240, and LBBB groups (0.6%, 0%, and 1.1%, respectively). Delayed HAVB (&gt;24 hours post-TAVR) was most frequent in the RBBB group (6.5% vs 1.5%; <em>P</em> &lt; .001), with higher incidence also observed in PR &gt;240 and LBBB groups compared with that in control (4.5% vs 1.5%; <em>P</em> = .14; and 4.3% vs 1.5%; <em>P</em> = .06, respectivley). Most of HAVB events in the control, isolated PR &gt;240 and LBBB groups were delayed.</div></div><div><h3>Conclusions</h3><div>Despite no immediate change in post-TAVR ECG, 17.8% of patients with preexisting RBBB developed HAVB, mostly within 24 hours. This emphasizes the need for inpatient monitoring for at least 24 hours in this group. Conversely, in patients with isolated PR &gt;240 milliseconds and LBBB, the incidence of HAVB was relatively low (5%), with the majority occurring after 24 hours. Potentially, same-day discharge with ambulatory ECG monitoring may be suitable for these patients.</div></div>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 7","pages":"Article 103666"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144680145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synchronizing the Beat: The Art and Science of Intracardiac Device Implantation","authors":"Naveen Vuppuluri DO,&nbsp;Ali Shakir MD","doi":"10.1016/j.jscai.2025.103717","DOIUrl":"10.1016/j.jscai.2025.103717","url":null,"abstract":"<div><div>This is the case report of a 90-year-old woman with multiple prior valvular interventions and severe tricuspid regurgitation who underwent successful percutaneous tricuspid valve replacement with an EVOQUE bioprosthesis (Edwards Lifesciences). Despite initial success, she developed a right bundle branch block and high-degree atrioventricular block resulting in a traumatic syncopal episode, necessitating leadless pacemaker insertion. This case highlights the advancements in valvular interventions and intracardiac devices and the impact they have had in transforming the field of structural heart disease. We discuss the new challenges for interventionalists and electrophysiologists in device selection and the potential benefits of leadless pacemakers in patients with complex cardiac histories.</div></div>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 7","pages":"Article 103717"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144680147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aortic Valve Replacement in Asymptomatic Severe Aortic Stenosis: A Systematic Review and Meta-Analysis","authors":"Philippe Généreux MD ,&nbsp;Marko Banovic MD, PhD ,&nbsp;Duk-Hyun Kang MD, PhD ,&nbsp;Gennaro Giustino MD ,&nbsp;Bernard D. Prendergast MD ,&nbsp;Brian R. Lindman MD ,&nbsp;David E. Newby MD, PhD ,&nbsp;Philippe Pibarot DVM, PhD ,&nbsp;Björn Redfors MD, PhD ,&nbsp;Allan Schwartz MD ,&nbsp;Roxanna Seyedin PhD, MPH ,&nbsp;Bernard Iung MD ,&nbsp;Marc R. Dweck MD, PhD","doi":"10.1016/j.jscai.2025.103663","DOIUrl":"10.1016/j.jscai.2025.103663","url":null,"abstract":"<div><h3>Background</h3><div>Current guidelines recommend a strategy of clinical surveillance (CS) for patients with asymptomatic severe aortic stenosis and normal left ventricular ejection fraction.</div></div><div><h3>Methods</h3><div>PubMed, Embase, and <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> were searched through November 2024 for randomized controlled trials (RCTs) and observational studies comparing surgical aortic valve replacement or transcatheter aortic valve replacement with CS in patients with asymptomatic severe aortic stenosis.</div></div><div><h3>Results</h3><div>Sixteen eligible studies (12 observational studies and 4 RCTs) were identified, with a total of 3919 patients in the observational studies and 1427 patients in the RCTs. In the pooled analyses combining observational studies and RCTs, aortic valve replacement (AVR) was associated with significantly reduced all-cause mortality (incidence rate ratio [IRR], 0.42; 95% CI, 0.31-0.58; <em>P</em> &lt; .01; <em>I</em>^<em>2</em> = 72%), cardiovascular mortality (IRR, 0.46; 95% CI, 0.28-0.78; <em>P</em> &lt; .01; <em>I</em>^<em>2</em> = 68%), and unplanned cardiovascular or heart failure (HF)-related hospitalization (IRR, 0.34; 95% CI, 0.21-0.55; <em>P</em> &lt; .01; <em>I</em>^<em>2</em> = 50%). In 12 observational studies, AVR was associated with significantly lower rates of all-cause mortality (IRR, 0.36; 95% CI, 0.27-0.49; <em>P</em> &lt; .01; <em>I</em>^<em>2</em> = 65%), and cardiovascular mortality (IRR, 0.33; 95% CI, 0.16-0.70; <em>P</em> &lt; .01; <em>I</em>^<em>2</em> = 71%) compared with CS. In 4 RCTs, there was no significant difference in all-cause or cardiovascular mortality, but AVR was associated with a significant reduction in unplanned cardiovascular or HF hospitalization (IRR, 0.42; 95% CI, 0.26-0.65; <em>P</em> &lt; .01; <em>I</em>^<em>2</em> = 27%) and stroke (IRR, 0.63; 95% CI, 0.40-0.98<em>; P</em> = .04; <em>I</em>^<em>2</em> = 0%).</div></div><div><h3>Conclusions</h3><div>Data from observational studies and recent RCTs suggest that a strategy of preemptive AVR is associated with improved survival and lower rates of unplanned cardiovascular or HF-related hospitalizations and stroke compared to CS.</div></div>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 7","pages":"Article 103663"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144680671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Experience With a Novel Perfusion Balloon Catheter in Patients With Coronary Artery Perforation: Primary Results From the Ringer Clinical Study","authors":"David E. Kandzari MD ,&nbsp;Mohammad Alqarqaz MD ,&nbsp;William J. Nicholson MD ,&nbsp;Kathleen E. Kearney MD ,&nbsp;Christopher E. Buller MD ,&nbsp;Ecaterina Cristea MD ,&nbsp;Alexandra J. Lansky MD","doi":"10.1016/j.jscai.2025.103575","DOIUrl":"10.1016/j.jscai.2025.103575","url":null,"abstract":"<div><h3>Background</h3><div>The Ringer perfusion catheter (Teleflex) features a novel design with a spiral-shaped inflatable balloon that approximates a hollow cylinder when inflated to manage hemorrhage associated with coronary artery perforation (CAP) during percutaneous coronary intervention while enabling distal perfusion.</div></div><div><h3>Methods</h3><div>In a multicenter, prospective, single-arm study, the safety and efficacy of using the Ringer device in the treatment of CAP were assessed. The primary efficacy end point included successful Ringer delivery across the perforation site, angiographic confirmation of no extravasation with balloon inflation, and demonstration of antegrade coronary flow. The primary safety end point was freedom from device-related thrombosis and coronary dissection. Clinical and angiographic outcomes were independently adjudicated.</div></div><div><h3>Results</h3><div>Among 30 patients with CAP, lesion characteristics included: chronic total occlusion, 50%; severe calcification, 63.3%; lesion length 34.1 ± 23.4 mm. Ellis type II and III perforations occurred in 50% and 30% of patients, respectively. For all patients, the primary efficacy end point was 73.3% by intention to treat analysis. However, among the 26 patients with successful Ringer delivery across the perforation site, the primary end point was 84.6%. In this latter group, acute resolution of contrast extravasation was 84.6%, and maintenance of thrombolysis in myocardial infarction 2/3 antegrade flow during device inflation was 100%. No device-related safety events were observed.</div></div><div><h3>Conclusions</h3><div>Treatment of CAP with a novel perfusion balloon catheter achieved favorable rates of deliverability and reduction in hemorrhage while maintaining antegrade flow. These results demonstrate that the Ringer perfusion catheter is a safe and effective method to manage CAP until definitive treatment is decided.</div></div>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 7","pages":"Article 103575"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144680706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in the Use of Atherectomy and Intravascular Lithotripsy for Percutaneous Coronary Intervention","authors":"Kyu Lee MD ,&nbsp;Priya Roy MD ,&nbsp;Umair Ahmad MD ,&nbsp;Paul S. Chan MSc, MD ,&nbsp;Richard J. Gumina MD, PhD ,&nbsp;Kevin Kennedy MSc ,&nbsp;Vittal Hejjaji MSc, MD ,&nbsp;Ali O. Malik MSc, MD","doi":"10.1016/j.jscai.2025.103615","DOIUrl":"10.1016/j.jscai.2025.103615","url":null,"abstract":"<div><h3>Background</h3><div>Atherectomy and intravascular lithotripsy (IVL) facilitate percutaneous coronary intervention (PCI) in calcified coronary disease, and use of these technologies is associated with greater luminal gain and superior intervention success. As atherectomy/IVL gain more widespread acceptance, it is important to understand whether their use differs across levels of social deprivation.</div></div><div><h3>Methods</h3><div>Within the National Cardiovascular Data Registry CathPCI Registry, we identified 310,124 patients who had a PCI for severely calcified lesions between 2018 and 2023. For each patient, we determined their social deprivation index (SDI) based on residential zip codes. The SDI is a composite measure of area-level social deprivation, with higher values correlating to greater deprivation. Hierarchical logistic regression models evaluated the association of SDI with use of atherectomy/IVL.</div></div><div><h3>Results</h3><div>Mean age was 70.9 ± 10.6 years, 69.4% were men, and 82.3% were of White race. Atherectomy/IVL was used in 33.0% of PCIs in severely calcified arteries. There was an inverse, graded relationship between SDI and atherectomy/IVL use. These differences were only partially attenuated after adjusting for patient and PCI characteristics. Compared with those residing in neighborhoods with the lowest quartile of social deprivation, those in the third and fourth quartiles of social deprivation were 10% (odds ratio, 0.90; 95% CI, 0.88-0.92; <em>P</em> &lt; .001) and 8% (odds ratio, 0.92; 95% CI, 0.90-0.94; <em>P</em> &lt; .001), respectively, less likely to have atherectomy/IVL used during PCI.</div></div><div><h3>Conclusions</h3><div>In the United States, greater social deprivation was associated with lower rates of atherectomy/IVL during PCI for severely calcified coronary artery stenoses, highlighting potential disparities in use of these technologies.</div></div>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 7","pages":"Article 103615"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144680135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Letter to the Editor Re: ChatGPT and CathSAP","authors":"Saumya Nanda MBBS,&nbsp;Partha Sardar MD,&nbsp;Saurav Chatterjee MD","doi":"10.1016/j.jscai.2025.103734","DOIUrl":"10.1016/j.jscai.2025.103734","url":null,"abstract":"","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 7","pages":"Article 103734"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144680672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Robotic-Assisted Percutaneous Coronary Intervention: Final Results of the PRECISION and PRECISION GRX Studies","authors":"Ehtisham Mahmud MD ,&nbsp;Ryan D. Madder MD ,&nbsp;David H. Wohns MD ,&nbsp;Jeffrey M. Schussler MD ,&nbsp;Adam Salisbury MD ,&nbsp;Paul Campbell MD ,&nbsp;Tejas M. Patel MD ,&nbsp;William L. Lombardi MD ,&nbsp;William J. Nicholson MD ,&nbsp;Manish A. Parikh MD ,&nbsp;Natia Kelm MD, PhD ,&nbsp;Ron Waksman MD ,&nbsp;Alexandra J. Lansky MD ,&nbsp;Giora Weisz MD","doi":"10.1016/j.jscai.2025.103655","DOIUrl":"10.1016/j.jscai.2025.103655","url":null,"abstract":"<div><h3>Background</h3><div>Robotic percutaneous coronary intervention (R-PCI) reduces occupational hazards for interventional cardiologists. However, there is a lack of clinical data in a large patient cohort. The aims of this study were to evaluate the safety and efficacy of R-PCI with both the first (CorPath 200) and second (CorPath GRX) (Corindus, Siemens Company) generation robotic systems.</div></div><div><h3>Methods</h3><div>These prospective, multicenter, single-armed studies enrolled patients with symptomatic coronary artery disease from 2013-2017 (PRECISION; CorPath 200) and 2017-2020 (PRECISION GRX; CorPath GRX). The primary outcome measures were clinical success, defined as &lt;30% residual stenosis in the absence of major adverse cardiovascular events, and technical success, defined as clinical success without conversion to manual PCI.</div></div><div><h3>Results</h3><div>A total of 1734 R-PCI procedures (PRECISION: 754 procedures, 950 lesions; PRECISION GRX: 980 procedures, 1233 lesions) were performed. Clinical (96.9% and 98.1% PRECISION and PRECISION GRX respectively, <em>P</em> = ns) and technical (89.6% and 89.2% PRECISION and PRECISION GRX respectively, <em>P</em> = ns) success rates were similar. Higher clinical success rates were observed in moderate/severe calcification lesions, bifurcation lesions, and long lesions with the second-generation system, and higher technical success rates were observed with the second-generation system in moderate/severe calcification lesions, bifurcation lesions, and angulated lesions.</div></div><div><h3>Conclusions</h3><div>This multicenter experience with R-PCI demonstrates high clinical and technical success for patients treated with either the first- or second-generation robotic platform. Clinical and technical success rates with the second-generation robotic platform were higher for several complex lesion types. These data support the safety and efficacy of R-PCI in clinical practice.</div></div>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 7","pages":"Article 103655"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144680705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}